What is Ethris?
Ethris operates at the intersection of genetic medicine and respiratory health, utilizing a proprietary technology platform to discover and develop innovative mRNA-based therapies. Unlike traditional approaches, the company specializes in the stabilization and direct delivery of mRNA to the respiratory system through advanced nebulization technologies. This unique capability allows for the precise administration of immuno-modulation and protein replacement treatments, addressing significant unmet needs in patient care. As a global leader in mRNA science, Ethris maintains a competitive edge by focusing on non-immunogenic delivery, which minimizes adverse patient responses while maximizing therapeutic efficacy. The company's pipeline is strategically designed to transform the treatment landscape for chronic and acute respiratory conditions, positioning it as a high-value asset in the broader biopharmaceutical ecosystem.
How much funding has Ethris raised?
Ethris has raised a total of $59.3M across 3 funding rounds:
Series A
$28M
Series B
$26.3M
Other Financing Round
$5M
Series A (2017): $28M with participation from HS Life Sciences and Orbimed
Series B (2022): $26.3M led by Laureus Capital
Other Financing Round (2024): $5M supported by Bill & Melinda Gates Foundation
Key Investors in Ethris
Laureus Capital
A group of serial entrepreneurs and investors focusing on digital innovation, sustainability, and diverse asset classes including technology and real estate.
Bill & Melinda Gates Foundation
A global philanthropic organization dedicated to improving healthcare outcomes and reducing extreme poverty through strategic investments in medical research and development.
Orbimed
A leading healthcare-dedicated investment firm that provides capital to companies across the life sciences spectrum, from early-stage startups to large-cap corporations.
What's next for Ethris?
With the successful closure of this latest financing round, Ethris is well-positioned to accelerate its clinical pipeline and refine its proprietary formulation technologies. The strategic focus will likely shift toward scaling manufacturing capabilities and advancing lead candidates through critical regulatory milestones. By maintaining its commitment to mRNA-based protein replacement, the company aims to solidify its market leadership and expand its therapeutic reach. Future growth will be driven by the continued validation of its nebulization platform, which serves as a key differentiator in the competitive landscape of genetic medicine. Investors and industry observers will be closely monitoring the company's progress as it transitions from a research-heavy entity to a clinical-stage powerhouse, potentially unlocking new avenues for patient-centric therapeutic interventions.
See full Ethris company page
